Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: A case report and a short review of the literature

Journal of Crohn's and Colitis

Volumn 7, Issue 2, 2013, Pages

  Chaparro, María ^a   Trapero Marugán, María ^a   Guijarro, Mercedes ^a   López, Consuelo ^a   Moreno Otero, Ricardo ^a   Gisbert, Javier P ^a  

^a Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

Author keywords

Dysplasia and colorectal cancer; Primary sclerosing cholangitis; Ulcerative colitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; COTRIMOXAZOLE; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOODY DIARRHEA; CASE REPORT; COLON BIOPSY; COLONOSCOPY; COLORECTAL CANCER; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE INCREASE; GASTROINTESTINAL DYSPLASIA; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; TUBERCULIN TEST; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CHOLANGITIS, SCLEROSING; COLECTOMY; COLITIS, ULCERATIVE; COLON; COLORECTAL NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE;

EID: 84872486561     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.04.005     Document Type: Article

References (45)

1. Wiesner R.H., LaRusso N.F. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology Aug. 1980, 79(2):200-206.
2. Thompson H.H., Pitt H.A., Tompkins R.K., Longmire W.P. Primary sclerosing cholangitis: a heterogenous disease. Ann Surg Aug. 1982, 196(2):127-136.
3. Lee Y.M., Kaplan M.M. Primary sclerosing cholangitis. N Engl J Med Apr. 6 1995, 332(14):924-933.
4. Fausa O., Schrumpf E., Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis Feb. 1991, 11(1):31-39.
5. Soetikno R.M., Lin O.S., Heidenreich P.A., Young H.S., Blackstone M.O. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc Jul. 2002, 56(1):48-54.
6. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut Apr. 2001, 48(4):526-535.
7. Wolf J.M., Rybicki L.A., Lashner B.A. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther Nov. 1 2005, 22(9):783-788.
8. Broome U., Lofberg R., Lundqvist K., Veress B. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum Dec. 1995, 38(12):1301-1305.
9. Lundqvist K., Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum Apr. 1997, 40(4):451-456.
10. Kitiyakara T., Chapman R.W. Chemoprevention and screening in primary sclerosing cholangitis. Postgrad Med J May 2008, 84(991):228-237.
11. Biancone L., Michetti P., Travis S., Escher J.C., Moser G., Forbes A., et al. European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohns Colitis Mar. 2008, 2(1):63-92.
12. Farraye F.A., Odze R.D., Eaden J., Itzkowitz S.H., McCabe R.P., Dassopoulos T., et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology Feb. 2010, 138(2):738-745.
13. Cairns S.R., Scholefield J.H., Steele R.J., Dunlop M.G., Thomas H.J., Evans G.D., et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut May 2010, 59(5):666-689.
14. Ahmadi A., Polyak S., Draganov P.V. Colorectal cancer surveillance in inflammatory bowel disease: the search continues. World J Gastroenterol Jan. 7 2009, 15(1):61-66.
15. Riddell R.H., Goldman H., Ransohoff D.F., Appelman H.D., Fenoglio C.M., Haggitt R.C., et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol Nov. 1983, 14(11):931-968.
16. Xie J., Itzkowitz S.H. Cancer in inflammatory bowel disease. World J Gastroenterol Jan. 21 2008, 14(3):378-389.
17. Connell W.R., Lennard-Jones J.E., Williams C.B., Talbot I.C., Price A.B., Wilkinson K.H. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology Oct. 1994, 107(4):934-944.
18. Ullman T., Croog V., Harpaz N., Sachar D., Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology Nov. 2003, 125(5):1311-1319.
19. Ullman T.A., Loftus E.V., Kakar S., Burgart L.J., Sandborn W.J., Tremaine W.J. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol Apr. 2002, 97(4):922-927.
20. Befrits R., Ljung T., Jaramillo E., Rubio C. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum May 2002, 45(5):615-620.
21. Lim C.H., Dixon M.F., Vail A., Forman D., Lynch D.A., Axon A.T. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut Aug. 2003, 52(8):1127-1132.
22. Zisman T.L., Rubin D.T. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol May 7 2008, 14(17):2662-2669.
23. Velayos FS, Liu L, Lewis JD, Allison JE, Flowers N, Hutfless S, et al. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology Nov;139(5):1511-8.
24. Hudson B., Green J. British Society of Gastroenterology guidelines for ulcerative colitis surveillance: creating consensus or confusion?. Gut Jul. 2006, 55(7):1052-1053.
25. Rodriguez S.A., Collins J.M., Knigge K.L., Eisen G.M. Surveillance and management of dysplasia in ulcerative colitis. Gastrointest Endosc Mar. 2007, 65(3):432-439.
26. Itzkowitz S.H. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am Sep. 2006, 35(3):553-571.
27. Pinczowski D., Ekbom A., Baron J., Yuen J., Adami H.O. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology Jul. 1994, 107(1):117-120.
28. Eaden J., Abrams K., Ekbom A., Jackson E., Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000 Feb, 14(2):145-153.
29. van Staa T.P., Card T., Logan R.F., Leufkens H.G. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut Nov. 2005, 54(11):1573-1578.
30. Velayos F.S., Loftus E.V., Jess T., Harmsen W.S., Bida J., Zinsmeister A.R., et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology Jun. 2006, 130(7):1941-1949.
31. Jess T., Loftus E.V., Velayos F.S., Winther K.V., Tremaine W.J., Zinsmeister A.R., et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol Apr. 2007, 102(4):829-836.
32. Terdiman J.P., Steinbuch M., Blumentals W.A., Ullman T.A., Rubin D.T. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis Apr. 2007, 13(4):367-371.
33. Bernstein C.N., Nugent Z., Blanchard J.F. 5-Aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol Apr. 2011, 106(4):731-736.
34. van Schaik F.D., van Oijen M.G., Smeets H.M., van der Heijden G.J., Siersema P.D., Oldenburg B. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut Feb. 2012, 61(2):235-240.
35. Beaugerie L., Seksik P., Bouvier A., Carbonnel F., Colombel J., Faivre J., et al. Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with longstanding extensive colitis: results from the CESAME cohort. Gastroenterology 2009, 139.
36. Carrat F., Seksik P., Bouvier A., Brousse N., Carbonnel F., Colombel J., et al. Aminosalicylates, thiopurines and the risk of colorectal cancer in inflammatory bowel disease: a case-control study nested in the CESAME cohort. Gastroenterology 2010, 138.
37. Pardi D.S., Loftus E.V., Kremers W.K., Keach J., Lindor K.D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology Apr. 2003, 124(4):889-893.
38. Eaton J.E., Silveira M.G., Pardi D.S., Sinakos E., Kowdley K.V., Luketic V.A., et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol Sep. 2011, 106(9):1638-1645.
39. Bergeron V, Vienne A, Sokol H, Seksik P, Nion-Larmurier I, Ruskone-Fourmestraux A, et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. Am J Gastroenterol Nov;105(11):2405-11.
40. Gupta R.B., Harpaz N., Itzkowitz S., Hossain S., Matula S., Kornbluth A., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology Oct. 2007, 133(4):1099-1105. [quiz 340-1].
41. Jess T., Loftus E.V., Velayos F.S., Harmsen W.S., Zinsmeister A.R., Smyrk T.C., et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis Aug. 2006, 12(8):669-676.
42. Kekilli M, Dagli U, Kalkan IH, Tunc B, Disibeyaz S, Ulker A, et al. Low incidence of colorectal dysplasia and cancer among patients with ulcerative colitis: a Turkish referral centre study. Scand J Gastroenterol Apr;45(4):434-9.
43. Lakatos L., Mester G., Erdelyi Z., David G., Pandur T., Balogh M., et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis Mar. 2006, 12(3):205-211.
44. Rutter M., Saunders B., Wilkinson K., Rumbles S., Schofield G., Kamm M., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology Feb. 2004, 126(2):451-459.
45. Shetty K., Rybicki L., Brzezinski A., Carey W.D., Lashner B.A. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol Jun. 1999, 94(6):1643-1649.